Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

Rhea-AI Summary

Titan Medical reported financial results for Q3 and nine months ended September 30, 2022. The company continues to pursue compliance with Nasdaq listing requirements, planning a shareholder meeting on January 12, 2023, to approve a common share consolidation. As of September 30, Titan had cash of $11.6 million, a decrease from $32.3 million at year-end 2021. R&D expenses for Q3 were $7.6 million, a reduction compared to the previous year, and G&A expenses also declined. The company is advancing the Enos surgical system with anticipated FDA application in mid-2023.

Positive

• R&D expenses decreased from $10.7 million to $7.6 million for Q3 2022, indicating cost control efforts.
• Continued progress on the Enos system with expected FDA IDE application submission in mid-2023.

Negative

• Cash and cash equivalents dropped significantly from $32.3 million at December 31, 2021, to $11.6 million by September 30, 2022.
• Failure to comply with Nasdaq's minimum bid requirement may lead to potential delisting.

Shareholder Meeting to Support Share Consolidation to Maintain Nasdaq Listing

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and nine months ended September 30, 2022. Additionally, the company announced that a special meeting of shareholders will be held virtually on January 12, 2023 to seek shareholder approval for a consolidation of its common shares, including for the purposes of demonstrating compliance with Nasdaq Rule 5550(a)(2).

As previously shared, Nasdaq granted the company with an extension to regain compliance with Nasdaq Rule 5550(a)(2), which requires an issuer to maintain a minimum bid price of at least US$1.00 for a minimum of 10 consecutive business days (and generally not more than 20 consecutive business days, in Nasdaq’s discretion). While the company continues to undertake initiatives directed at increasing shareholder value, should the company not be able to evidence compliance prior to December 26, 2022, the company expects Nasdaq to notify Titan that its shares are subject to delisting. At such time, the company would likely appeal such determination and it is expected that the company’s shares would continue to be listed and available to trade on Nasdaq at least pending the completion of the appeal process. The share consolidation, if approved, would likely be the last option available to the company to regain compliance with the minimum bid price requirement and maintain its Nasdaq listing.

“Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022. We are excited and ready to commence verification, validation and safety testing on the delivered unit in support of the planned IDE submission to the FDA in 2023. Following submission, we expect to finalize our clinical trial design and continue to plan our commercialization strategy for the U.S. market. We have worked closely with our manufacturing partners in an effort to circumvent supply chain disruptions and are excited about our progress to date at this stage of the production cycle. We are committed to working with surgeons to improved patient outcomes using minimally invasive robotic surgery,” stated Cary G. Vance, Titan’s President and CEO.

Vance added, “After careful consideration, the company has also decided to propose a consolidation of common shares to its shareholders. We believe that a consolidation is in the best interests of shareholders, including for the purposes of regaining compliance with Nasdaq listing requirements. A continued Nasdaq listing provides numerous benefits to the company, including increased visibility of the company amongst U.S. analysts and investors, increased access to capital including potentially institutional investors, and the potential for greater trading volume and liquidity for the company’s common shares. We look forward to providing additional details of the special meeting.”

Recent Company Activities and Progress

• Cary Vance participated on a panel during The MedTech Conference held in Boston on October 24-26, 2022
  • Mr. Vance and other leaders discussed navigating regulatory and business considerations in surgical robotics innovation

• Appointed Eric Heinz as Vice President, Market and Corporate Development
  • Mr. Heinz is responsible for developing and executing on strategic business plans to expand and accelerate Titan’s Enos™ robotic single access surgical system’s portfolio cadence

• Completion of manufacturing transfer to Benchmark
  • Titan has substantially completed the transfer of the Enos System to manufacturing, including the areas of supply chain management, product assembly and testing, and implementation of software updates related to safety controls

• Continued FDA communications via Q-Submission process
  • Received helpful feedback from the FDA on last Q-submission utilizing this effective process

• Continued strengthening of intellectual property
  • Filings include innovations in next generation single access RAS technology

• Signed a limited development and supply agreement with Medtronic
  • The company will support Medtronic with limited development and pre-clinical activities through the supply of instruments and cameras

• Presented at the H.C. Wainwright Global Investment Conference held on September 12-14, 2022 and participated in investor meetings
  

The company plans to pursue a De Novo regulatory process for marketing authorization with the U.S. Food and Drug Administration (FDA). Utilizing the Q-Submission program, the company has engaged in ongoing dialogue with the FDA to clarify requirements in an effort to mitigate against timeline risks. The company plans to file the IDE application with the FDA mid-year 2023 for its initial target indication for benign gynecologic surgical procedures. Titan anticipates receiving a response on the IDE application from the FDA in the second half of 2023. Following IDE approval, Titan expects to proceed with and complete a clinical study in time for submission of a De Novo classification request with the FDA in 2024. Commercial launch of the Enos™ single access RAS system is scheduled to begin upon receipt of marketing authorization from the FDA.

Financial Highlights Summary

As of September 30, 2022, Titan had cash and cash equivalents of $11.6 million, compared to $32.3 million at December 31, 2021.

For the three months ended September 30, 2022, R&D expenses were to $7.6 million compared to $10.7 million for the for the three months ended September 30, 2021. R&D expenses for the three-month period ending September 30, 2022 were related to the development of the Enos System and an increase in labor costs as the Company continues to add the required resources to its engineering, regulatory and quality teams to advance the Enos System.

R&D expenses were $26.7 million for the nine months ended September 30, 2022 compared to $28.4 million for the nine months ended September 30, 2021. R&D expenses for the nine-month period ending September 30, 2022 were related to the development of the Enos System and an increase in labor costs. In the comparative period, R&D expenses related to the development of the Enos System and the development work required to achieve the milestones under the Development Agreement with Medtronic.

G&A expenses were $3.0 million for the three months ended September 30, 2022 compared to $3.4 million for the three months ended September 30, 2021. The decrease in G&A expenses in the three-month period is related to a decrease in stock-based compensation of $0.4 million.

For the nine-month period ended September 30, 2022, G&A expenses were $8.7 million compared to $9.6 million in the comparative period. The decrease in G&A expenses in the nine-month period is primarily related to a decrease in stock-based compensation of $1.8 million and a decrease in professional and consulting fees partially offset by an increase in severance costs, public company costs and recruitment fees related to filling open roles on the senior leadership team.

The company’s interim financial statements and MD&A are available at www.sedar.com and at www.sec.gov.

Investor Audio Webcast Information

Titan Medical will host an investor audio webcast at 8:30 a.m. ET today (November 10, 2022) to discuss the company’s financial results for the three months ended September 30, 2022, and recent business highlights. The webcast can be accessed via the Investor Relations section of the company’s website www.titanmedicalinc.com.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

Enos™ is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the company’s future growth, results of operations, performance, and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the company’s focus on surgical technologies for single access RAS; the company’s plans and expectations with respect to timing for regulatory submissions, including for an IDE application and De Novo application, clinical trials and the commercialization of the Enos system; the company’s plans for verification, validation and safety testing to support its IDE submission to the FDA in 2023; the company’s dialogue with the FDA and utilization of the Q-Submission program to mitigate against timeline risks; the company’s plans to increase shareholder value and otherwise demonstrate and regain compliance with Nasdaq Rule 5550(a)(2); the company’s plans to hold a special shareholder meeting; the potential benefits of a continued Nasdaq listing; the company’s efforts to circumvent supply chain disruptions; the company’s intention to host an upcoming investor audio webcast; the Enos system being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements; and the company’s intention to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties, and assumptions. Many factors could cause the company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the company’s Annual Report for the fiscal year ended December 31, 2021, which may be viewed at www.sedar.com and at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact
Kristen Galfetti
Vice President, Investor Relations
   & Corporate Communications
+1-781-869-2553
investors@titanmedicalinc.com

Titan Medical Inc.
Interim Consolidated Statements of Financial Position
(In thousands of US dollars)
			9/30/2022			12/31/2021
Assets			$			$
CURRENT ASSETS
	Cash and cash equivalents		11,636			32,306
	Receivables		-			8,280
	Prepaid expenses, deposits and receivables		2,367			3,076
TOTAL CURRENT ASSETS			14,003			43,662
NON-CURRENT ASSETS
	Right-of-use assets, net		1,301			1,177
	Property and equipment, net		736			464
	Patent rights, net		2,031			1,919
TOTAL NON-CURRENT ASSETS			4,068			3,560
Total assets			18,071			47,222
Liabilities
CURRENT LIABILITIES
	Accounts payable and accrued liabilities		8,335			5,616
	Current portion of lease liabilities		320			346
	Deferred revenue		1,206			-
	Warrant derivative liability		39			4,930
TOTAL CURRENT LIABILITIES			9,900			10,892
NON-CURRENT LIABILITIES
Deferred income tax labilities			56			56
Long-term lease liabilities			1,160			981
Total Liabilities			11,116			11,929
Shareholders' equity
Share capital			264,460			263,364
Contributed surplus-Warrant reserve			11,749			11,749
Contributed surplus			15,107			14,067
Deficit			(284,361	)		(253,887	)
Shareholders' equity			6,955			35,293
Total liabilities and Shareholders' equity			18,071			47,222

Titan Medical Inc.
Interim Consolidated Statements of Net and Comprehensive Loss
(In thousands of US dollars, except share and per share amount)
	Three Months Ended Sept 30						Nine Months Ended Sept 30
	2022			2021			2022			2021
	$			$			$			$
Revenues	-			-			-			10,093
Expenses
Research and development	7,612			10,714			26,721			28,358
General and administrative	3,008			3,358			8,668			9,565
Depreciation	-			-			-			-
Total expenses	10,620			14,072			35,389			37,923
Net loss from operations	(10,620	)		(14,072	)		(35,389	)		(27,830	)
Other Expenses (Income)
Finance income	(34	)		(20	)		(95	)		(53	)
Finance expense	42			60			77			60
Foreign exchange (gain) loss	(34	)		(3	)		(6	)		56
Gain on fair value of warrant	(224	)		(5,554	)		(4,891	)		(3,604	)
Total other income	(250	)		(5,517	)		(4,915	)		(3,541	)
Net and comprehensive loss	(10,370	)		(8,555	)		(30,474	)		(24,289	)
Basic and fully diluted loss per share	(0.09	)		(0.08	)		(0.27	)		(0.23	)
Weighted average number of common shares
Basic and diluted	111,664,823			111,127,690			111,397,231			107,520,004

Titan Medical Inc.
Interim Consolidated Statements of Cash Flows
(In thousands of US dollars)
			Nine Months Ended Sept 30
			2022			2021
			$			$
OPERATING ACTIVITIES
	Net loss and comprehensive loss		(30,474	)		(24,289	)
	Items not involving current cash flows:
		Depreciation and amortization	563			403
		Interest expense on lease liabilities	78			53
		Share-based compensation expense	2,134			3,620
		Gain on change in fair value of warrants	(4,891	)		(3,604	)
		Accrued interest on Note payable	-			115
		Warrant liability-foreign exchange adjustment	-			44
Changes in non-cash working capital balances
	Receivables		8,280			-
	Prepaid expenses and deposits		709			(223	)
	Accounts payable and accrued liabilities		2,719			(441	)
	Deferred revenues		1,206			-
Cash used in operating activities			(19,676	)		(24,322	)
FINANCING ACTIVITIES
	Exercise of Derivative warrants		2			8,000
	January 2021 Equity Offering, net of issuance costs		-			10,375
	February 2021 Equity Offering, net of issuance costs		-			21,093
	Exercise of Equity warrants		-			1,985
	Exercise of stock options		-			14
	Proceeds from issuance of common shares		-			2,709
	Note payable		-			135
	Repayment of lease liabilities		(308	)		(180	)
Cash (used in) provided by financing activities			(306	)		44,131
INVESTING ACTIVITIES
	Purchase of property, plant and equipment		(474	)		(333	)
	Purchase of patents		(214	)		(268	)
Cash used in investing activities			(688	)		(601	)
(Decrease) increase in cash and cash equivalents			(20,670	)		19,208
Cash and cash equivalents, beginning of the period			32,306			25,469
Cash and cash equivalents, end of the period			11,636			44,677

FAQ

What are Titan Medical's recent financial results for Q3 2022?

Titan Medical reported R&D expenses of $7.6 million for Q3 2022, with cash of $11.6 million as of September 30, 2022.

When is the shareholder meeting for Titan Medical regarding share consolidation?

The shareholder meeting is scheduled for January 12, 2023, to request approval for a common share consolidation.

What challenges is Titan Medical facing with its Nasdaq listing?

Titan Medical must comply with Nasdaq Rule 5550(a)(2) to maintain its listing, seeking to consolidate shares to meet the minimum bid requirement.

What are Titan Medical's plans for the Enos system?

Titan plans to submit an IDE application for the Enos system to the FDA in mid-2023 and is preparing for clinical trials.